Document Detail


Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease.
MedLine Citation:
PMID:  17943795     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Drugs that mimic dopamine, such as bromocriptine (BR), were introduced as monotherapy or in combination with levodopa (LD) in the hope that this approach would prevent or delay the onset of motor complications in patients with Parkinson's disease (PD). However, hitherto, the role of BR has remained controversial. We present a systematic review of all randomised controlled trials (RCTs) of BR/LD combination therapy compared with LD monotherapy in PD.
OBJECTIVES: To assess the efficacy and safety of BR/LD combination therapy in delaying the onset of motor complications associated with LD monotherapy in patients with PD.
SEARCH STRATEGY: We searched the Movement Disorders Group trials register which includes MEDLINE and EMBASE; the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library); handsearched appropriate neurology journals, symposia reports, PD handbooks and reference lists of reviews found by the search-strategy. We also contacted Sandoz -now Novartis- (manufacturer of BR) and PPD Pharmaco and contacted colleagues who had co-ordinated trials on BR.
SELECTION CRITERIA: RCTs were eligible for inclusion if they evaluated the efficacy of BR/LD combination therapy for delaying the onset of motor complications compared with LD monotherapy in patients with PD. Outcome measures evaluated included the occurrence and severity of motor complications, impairment and disability scores, side effects and dropouts.
DATA COLLECTION AND ANALYSIS: To determine the feasibility of a quantitative systematic review two independent reviewers evaluated the methodological quality of identified trials and extracted data from the trials.
MAIN RESULTS: The methodological quality of seven trials showed important shortcomings. All studies failed adequately to describe randomisation procedures. Only three were carried out according to a double-blind design. Differences were found between studies concerning the mean age of the participants, the BR titration phase, the maximum achieved daily dose of LD (62.5 to 1000 mg) and BR (5 to 50 mg), and the applied outcomes. Our results show no evidence of consistent differences between treatment groups concerning the occurrence and severity of motor complications, scores of impairment and disability, or the occurrence of side effects.
AUTHORS' CONCLUSIONS: This systematic review revealed no evidence to support the use of early BR/LD combination therapy as a strategy to prevent or delay the onset of motor complications in the treatment of PD.
Authors:
J J van Hilten; C C Ramaker; Rl Stowe; N J Ives
Related Documents :
11687085 - Anaesthesia for hip fracture surgery in adults.
8750375 - An automated patient registration and treatment randomization system.
11417025 - Randomised clinical trials: a source of ethical dilemmas.
20739355 - Patient safety and quality of care continue to improve in nhs north west following earl...
17111415 - Blue and red light combination led phototherapy for acne vulgaris in patients with skin...
8651085 - Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy a...
Publication Detail:
Type:  Journal Article; Review     Date:  2007-10-17
Journal Detail:
Title:  The Cochrane database of systematic reviews     Volume:  -     ISSN:  1469-493X     ISO Abbreviation:  Cochrane Database Syst Rev     Publication Date:  2007  
Date Detail:
Created Date:  2007-10-18     Completed Date:  2008-01-17     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  100909747     Medline TA:  Cochrane Database Syst Rev     Country:  England    
Other Details:
Languages:  eng     Pagination:  CD003634     Citation Subset:  IM    
Affiliation:
Leiden University Medical Center, Department of Neurology, P.O. Box 9600, Leiden. Netherlands, 2300 RC. J.J.van_Hilten@lumc.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antiparkinson Agents / therapeutic use*
Bromocriptine / therapeutic use*
Combined Modality Therapy
Humans
Levodopa / therapeutic use*
Parkinson Disease / drug therapy*
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
0/Antiparkinson Agents; 0/Levodopa; 25614-03-3/Bromocriptine
Comments/Corrections
Update Of:
Cochrane Database Syst Rev. 2002;(2):CD003634   [PMID:  12076493 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases.
Next Document:  Antibiotics for acute pyelonephritis in children.